Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04678154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

Study acronym: SEXTANT 2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Sep 30, 2026 → Sep 30, 2028
Enrollment reduced 50% 1200 → 600 participants
See other at-risk trials from Major Extremity Trauma Research Consortium

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 30, 2026 to Sep 30, 2028v9 Show 6 more changesShow less
    • Enrollment reduced: 1200 → 600 participants
    • Study completion pushed from Mar 31, 2027 to Mar 31, 2029
    • Eligibility criteria expanded, about 228 words
    • Secondary endpoints shortened, about 7 words
    • Study description expanded, about 56 words
    • Study title expanded, about 1 word
  2. Minor Re-verified, no change to tracked fieldsv8
  3. Notable Primary completion date: Sep 28, 2024 to Sep 30, 2026
    • Study sites: 33 to 31
    • Study completion date: Mar 30, 2025 to Mar 31, 2027
    v7
  4. Minor Study sites: 1 to 33v6
  5. Notable Primary completion date: Oct 28, 2023 to Sep 28, 2024
    • Study completion date: Mar 30, 2024 to Mar 30, 2025
    • Collaborators expanded, about 5 words
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv4
  2. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Feb 28, 2023 to Oct 28, 2023
    • Study sites: 0 to 1
    • Study completion date: Oct 1, 2024 to Mar 30, 2024
    • Start date changed from estimate of Jun 1, 2021 to May 7, 2021
  3. Notable Start date: Mar 1, 2021 to Jun 1, 2021v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The PRCT evaluates infection outcomes as well as fracture and antibiotic-related complications to include the emergence of resistant bacteria associated with two different antibiotic strategies in the treatment of Gustilo type IIIB tibia and hindfoot fractures (calcaneus and talus) and selected IIIA fractures of the tibia and trauma-related transtibial amputations that are performed in the "zone-of-injury". This study will be conducted in established METRC level 1 trauma centers. The patients will be randomized as close to admission as possible to either 1) Standard of Care (SOC) prophylactic open fracture protocol, including the use of topical antibiotic as per the usual practice of the surgeon or 2) experimental protocol (SEXTANT). The SEXTANT protocol includes application of wound bioburden-targeted topical Vancomycin powder and Tobramycin powder antibiotic treatment at the time of final wound closure/coverage combined with 72 hours of systemic antibiotic coverage targeted to both gram-positive and gram-negative pathogens. The study will compare the results of the current SOC prophylactic coverage to the strategic wound bioburden treatment (SEXTANT) protocol. Up until the time of definitive wound closure/coverage, all patients will be treated per the usual regimen of the surgeon / center and in accordance with current Trauma Quality Improvement Program (TQIP) and Surgical Quality Improvement Program (SQIP) recommendations for the care of open fractures.14,15,17 It includes the administration of systemic antibiotics as close to the time of injury as possible. In the definitive wound closure/coverage procedure post-operative period, participants in the intervention arm will receive 72 hours of systemic antibiotic therapy targeted at the modern wound bioburden, and patients in the usual care arm will receive post-operative care per the usual practice of their surgeon. All other activities related to follow-up and related treatments will proceed per the usual practice of the surgeon.
Trial Details
NCT Number NCT04678154
Lead Sponsor Major Extremity Trauma Research Consortium
Collaborators: United States Department of Defense
Conditions
(from sponsor)
Post Operative Surgical Site Infection
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov